LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers):
holder breadth +9.1% ·
share flow -2.3% ·
net new positions +8.3%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 193 | +4 | 671.92M | $804.91B | +6 | −1 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | — |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | — |
| Q2 2024 | 22 | — | 112.43M | $101.75B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 20.93M | +1.4% | $18.54B | 2.1% | ▲ Add | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 20.93M | +1.4% | $18.54B | 2.1% | ▲ Add | 2 | SEC ↗ |
| 3 | Capital World Investors ✦ | 20.36M | -6.7% | $18.03B | 2.8% | ▼ Trim | 2 | SEC ↗ |
| 4 | PRIMECAP Management ✦ | 17.69M | -9.8% | $15.67B | 11.5% | ▼ Trim | 2 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 17.09M | +0.5% | $15.09B | 1.2% | ▲ Add | 2 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 17.09M | +0.5% | $15.09B | 1.2% | ▲ Add | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 12 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 13 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 14 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 15 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 16 | Norges Bank ✦ (passive) | 10.49M | -4.7% | $9.29B | 1.3% | ▼ Trim | 2 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 5.06M | +3.5% | $4.48B | 1.8% | ▲ Add | 2 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 1.63M | +1.3% | $1.44B | 1.2% | ▲ Add | 2 | SEC ↗ |
| 19 | Millennium Management ✦ | 990.21K | +86.1% | $877.27M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 20 | Tiger Global Management ✦ | 969.80K | +4.3% | $859.18M | 3.7% | ▲ Add | 2 | SEC ↗ |
| 21 | Marshall Wace ✦ | 910.13K | +15.3% | $806.32M | 1.1% | ▲ Add | 2 | SEC ↗ |
| 22 | Marshall Wace ✦ | 910.13K | +15.3% | $806.32M | 1.1% | ▲ Add | 2 | SEC ↗ |
| 23 | Marshall Wace ✦ | 910.13K | +15.3% | $806.32M | 1.1% | ▲ Add | 2 | SEC ↗ |
| 24 | Adage Capital Partners ✦ | 829.38K | +0.2% | $734.78M | 1.3% | ▲ Add | 2 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 30 | D. E. Shaw & Co. ✦ | 408.08K | +72.0% | $361.54M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 31 | D. E. Shaw & Co. ✦ | 408.08K | +72.0% | $361.54M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 32 | Renaissance Technologies ✦ | 257.81K | New | $228.41M | 0.3% | New | 1 | SEC ↗ |
| 33 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 34 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 35 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 36 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 37 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 38 | Citadel Advisors ✦ | 215.18K | -57.0% | $190.64M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 39 | Citadel Advisors ✦ | 215.18K | -57.0% | $190.64M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 40 | Two Sigma Investments ✦ | 199.74K | -11.5% | $176.95M | 0.4% | ▼ Trim | 2 | SEC ↗ |
| 41 | Viking Global Investors ✦ | 152.04K | +5.5% | $134.70M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 42 | Bridgewater Associates ✦ | 73.27K | -23.5% | $64.91M | 0.4% | ▼ Trim | 2 | SEC ↗ |
| 43 | Dodge & Cox ✦ | 45.09K | -1.9% | $39.95M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 44 | GAMCO Investors ✦ | 34.81K | -2.8% | $30.84M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 45 | Point72 Asset Management ✦ | 13.16K | New | $11.66M | 0.0% | New | 1 | SEC ↗ |
| 46 | Gotham Asset Management ✦ | 8.52K | -28.7% | $7.54M | 0.1% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $228.41M | 0.3% |
| Point72 Asset Management | $11.66M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 4,323 holders, 762.84M shares, $674.93B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 6.50K sh · $7.64M
Officer · 2.00K sh · $2.37M
Officer · 5.00K sh · $5.95M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…
ForbesThe Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…
WSJThe U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of…
ReutersThe once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…
WSJEli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2…
Reuters